Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HTF1037
- Development stage
- Unknown
- Lead developer
- HighTide Therapeutics
- Modality
- Small Molecules
01
Overview
HTF1037 is a mitochondrial uncoupler being developed by HighTide Therapeutics for the treatment of obesity. It works by disrupting the normal coupling between nutrient oxidation and adenosine triphosphate (ATP) production within the mitochondria. By dissipating the proton gradient across the inner mitochondrial membrane, the drug increases metabolic fuel consumption and energy expenditure without a corresponding increase in ATP synthesis, potentially leading to significant weight loss. As of August 2025, HTF1037 is in Phase 1 clinical development.
Beyond the preview
Go deeper on HTF1037.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HTF1037.